Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura.

Thrombotic thrombocytopenic purpura (TTP) and the hemolytic uremic syndrome (HUS) are both characterized by thrombocytopenia, microangiopathic hemolysis, and organ dysfunction. Other disorders occasionally present with similar manifestations. Recent studies have demonstrated that deficiency in the von Willebrand factor cleaving protease ADAMTS13, due to genetic mutations or autoimmune inhibitors, causes TTP. Molecular cloning of ADAMTS13 elucidates the structure of the protease, raising the prospect for advances in diagnosis and treatment of the disease. Assay of ADAMTS13 activity distinguishes TTP from HUS and other types of thrombotic microangiopathy (TMA); therefore, the term TTP/HUS should be avoided because it obscures the known or potential differences among the various types of TMA.

[1]  J. Moake.  von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. , 2004, Seminars in hematology.

[2]  D. Ginsburg,et al.  ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity. , 2003, Blood.

[3]  H. Tsai,et al.  Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura , 2003, European journal of haematology.

[4]  G. Kobbe,et al.  Quantitative real‐time reverse‐transcription polymerase chain reaction for diagnosis of BCR‐ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation , 2003, European journal of haematology.

[5]  R. Sarode,et al.  Ultralarge von Willebrand factor multimers and normal ADAMTS13 activity in the umbilical cord blood. , 2002, Thrombosis research.

[6]  F. Zintl,et al.  Remission of thrombotic thrombocytopenic purpura in a patient with compound heterozygous deficiency of von Willebrand factor‐cleaving protease by infusion of solvent/detergent plasma , 2002, Acta paediatrica.

[7]  T. Miyata,et al.  Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[8]  N. Perico,et al.  von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. , 2002, Blood.

[9]  Miha Furlan,et al.  Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. , 2002, Blood.

[10]  L. Gutterman,et al.  Rituximab therapy for refractory thrombotic thrombocytopenic purpura. , 2002, Blood cells, molecules & diseases.

[11]  H. Tsai.  Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura , 2002, Journal of Molecular Medicine.

[12]  M. Ciol,et al.  Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. , 2002, The New England journal of medicine.

[13]  B. Lämmle,et al.  Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. , 2002, Blood.

[14]  N. Perico,et al.  von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. , 2002, Blood.

[15]  K. Fujikawa,et al.  Structure of von Willebrand Factor-cleaving Protease (ADAMTS13), a Metalloprotease Involved in Thrombotic Thrombocytopenic Purpura* , 2001, The Journal of Biological Chemistry.

[16]  P. Mannucci,et al.  Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. , 2001, Blood.

[17]  T. Foroud,et al.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura , 2001, Nature.

[18]  T. Hamamoto,et al.  A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? , 2001, Journal of biochemistry.

[19]  B. Lämmle,et al.  Partial amino acid sequence of purified von Willebrand factor-cleaving protease. , 2001, Blood.

[20]  J. Kelton,et al.  Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. , 2001, Blood.

[21]  A. Houllier,et al.  Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. , 2001, Blood.

[22]  K. Fujikawa,et al.  Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. , 2001, Blood.

[23]  Y. Ravindranath,et al.  Congenital microangiopathic hemolytic anemia and thrombocytopenia with unusually large von Willebrand factor multimers and von Willebrand factor-cleaving protease. , 2001, Journal of pediatric hematology/oncology.

[24]  Frcp C. Mark Taylor.  Hemolytic-Uremic Syndrome and Complement Factor H Deficiency: Clinical Aspects , 2001, Seminars in thrombosis and hemostasis.

[25]  Craig S. Wong,et al.  Von Willebrand Factor and Von Willebrand Factor-Cleaving Metalloprotease Activity in Escherichia coli O157:H7-Associated Hemolytic Uremic Syndrome , 2001, Pediatric Research.

[26]  B. Lämmle,et al.  Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor‐cleaving protease , 2001, British journal of haematology.

[27]  G. Hutchins,et al.  Von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy. , 2001, The hematology journal : the official journal of the European Haematology Association.

[28]  H. Tsai.  High titers of inhibitors of von Willebrand factor‐cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura , 2000, American journal of hematology.

[29]  R. Sarode,et al.  Antibody Inhibitors to von Willebrand Factor Metalloproteinase and Increased Binding of von Willebrand Factor to Platelets in Ticlopidine-Associated Thrombotic Thrombocytopenic Purpura , 2000, Annals of Internal Medicine.

[30]  J. Sixma,et al.  von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. , 1999, Blood.

[31]  L. Oleksowicz,et al.  Deficient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies. , 1999, Cancer research.

[32]  M. C. de Castillo,et al.  A clinical and bacteriological study of children suffering from haemolytic uraemic syndrome in Tucuman, Argentina. , 1999, Japanese journal of infectious diseases.

[33]  H. Tsai,et al.  Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. , 1998, The New England journal of medicine.

[34]  B. Lämmle,et al.  von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. , 1998, The New England journal of medicine.

[35]  S. Schulman,et al.  The pathogenesis and treatment of hemolytic uremic syndrome. , 1998, Journal of the American Society of Nephrology : JASN.

[36]  B. Lämmle,et al.  Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. , 1998, Blood.

[37]  J. Moake,et al.  Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura , 1998, American journal of hematology.

[38]  R. Nagel,et al.  Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: inhibition by doxycycline and by monoclonal antibody VP-1. , 1997, Blood.

[39]  B. Lämmle,et al.  Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. , 1997, Blood.

[40]  R. Marchant,et al.  Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. , 1996, Blood.

[41]  H. Tsai.  Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. , 1996, Blood.

[42]  B. Lämmle,et al.  Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. , 1996, Blood.

[43]  R. Nagel,et al.  Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. , 1994, Blood.

[44]  J. Kelton,et al.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. , 1991, The New England journal of medicine.

[45]  B. Wiedemann,et al.  Brief report: resistance development to fluoroquinolones in Europe , 1989 .

[46]  J. Moake,et al.  Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. , 1989, The American journal of medicine.

[47]  S. Sierakowski,et al.  Thrombotic thrombocytopenic purpura. A review. , 1988, Cor et vasa.

[48]  J. Carlson,et al.  A severe outbreak of Escherichia coli O157:H7--associated hemorrhagic colitis in a nursing home. , 1987, The New England journal of medicine.

[49]  H. Erickson,et al.  Substructure of human von Willebrand factor. , 1985, The Journal of clinical investigation.

[50]  J. Loscalzo,et al.  Native conformation of human von Willebrand protein. Analysis by electron microscopy and quasi-elastic light scattering. , 1985, The Journal of biological chemistry.

[51]  Y. Asada,et al.  Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. , 1985, Thrombosis research.

[52]  Bukowski Rm.  Thrombotic thrombocytopenic purpura: a review. , 1982 .